Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study reveals earlier heat risk thresholds for vulnerable seniors

23

Mar 2026

Study reveals earlier heat risk thresholds for vulnerable seniors

Nationally, heat-related mortality has risen by nearly 17 percent per year since 2016. As a result, New York City now issues heat alerts and opens cooling centers when the heat index is forecast to reach 95 degrees Fahrenheit or higher for at least two consecutive days or a heat index of 100 degrees Fahrenheit or higher for any length of time.

Replacing sedentary time improves insulin resistance in adolescents

23

Mar 2026

Replacing sedentary time improves insulin resistance in adolescents

Adolescents who replaced just half an hour of sedentary behaviors, such as sitting on the couch or spending time at the computer, each day for moderate-to-vigorous physical activity or sleep may lower their insulin resistance, a key factor in preventing the development of Type 2 diabetes, according to preliminary research presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026.

Early biomarker predicts cognitive impairment after out-of-hospital cardiac arrest

23

Mar 2026

Early biomarker predicts cognitive impairment after out-of-hospital cardiac arrest

Routine early measurement of neurofilament light chain could help improve prediction of cognitive impairment after out-of-hospital cardiac arrest, according to a study presented today at ESC Acute CardioVascular Care 2026, the annual congress of the Association for Acute CardioVascular Care (ACVC), a branch of the European Society of Cardiology (ESC).

Higher meat intake may slow cognitive decline in older adults with APOE ε4

22

Mar 2026

Higher meat intake may slow cognitive decline in older adults with APOE ε4

In older Swedish adults, higher meat intake was associated with slower cognitive decline and lower dementia risk among people carrying APOE ε3/ε4 or ε4/ε4, but not among other genotype groups. A higher processed-to-total meat ratio was linked to worse dementia outcomes, while unprocessed red meat and poultry showed no substantial difference.

U.S. study links ultra-processed foods to lower odds of fertility

22

Mar 2026

U.S. study links ultra-processed foods to lower odds of fertility

A cross-sectional NHANES study of 2,582 U.S. women found that higher ultra-processed food intake was associated with lower odds of being classified as fertile based on self-reported infertility history. Greater Mediterranean diet adherence was linked to higher odds of fertility in adjusted models, but that association was no longer significant after accounting for obesity.

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

22

Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

22

Mar 2026

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major cardiovascular events and end-stage kidney disease over five years. The study also found no increased risk of hospitalization for diabetic ketoacidosis or severe hypoglycemia, supporting further randomized trials of GLP-1RAs as adjunctive therapy in type 1 diabetes.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.